Dapoxetine
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Dapoxetine Product Information
Dapoxetine is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Dapoxetine. The product is supplied by Clearsynth under CAT No. CS-O-06323.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Dapoxetine
CAS No.
119356-77-3
CAT No.
CS-O-06323
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C21H23NO
Molecular Weight
305.41
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Dapoxetine is supplied with detailed characterization data compliant with regulatory guideline. Dapoxetine can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Dapoxetine.
Overview
"Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to"
Synonyms
Dapoxetine
Application Notes
"Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to"
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.